This axis is not only central to T1D but is also well-established in other autoimmune diseases such as psoriasis and inflammatory bowel disease (IBD), where IL-23 inhibitors have shown therapeutic success [130,133]. This evidence concerns the gene IL23A and type 1 diabetes mellitus.